Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Semin Oncol. 2015 Jun 3;42(4):601–616. doi: 10.1053/j.seminoncol.2015.05.007

Table 1.

Ongoing Clinical Trials of Combined Molecularly Targeted Therapy and Immunotherapy

Target Therapy and Checkpoint
Blockade		 Targeted Therapy and
Cytokine Therapy		 Targeted Therapy and
Adoptive Cell Therapy
Dabrafenib +/− trametinib +
ipilimumab (NCT01767454;
NCT01940809)		 Vemurafenib + high-dose
IL-2 (NCT01754376;
NCT 01683188)		 Vemurafenib + tumor-infiltrating
lymphocytes (NCT00338377;
NCT01585415; NCT01659151)
Vemurafenib + anti–PD-L1
(MPDL3280) (NCT01656642)		 Vemurafenib + IL-2
(infusional 96 hour) +
IFN-α (NCT01603212)
Dabrafenib + trametinib + anti–PD-1
(MK-3475) (NCT02130466)		 Vemurafenib + pegylated
IFN (NCT01959633)
Trametinib +/− dabrafenib + anti–PD-
L1 (MEDI4736) (NCT02027961)		 Vemurafenib + high-dose
IFN-α2b
(NCT01943422)
Dabrafenib + trametinib followed by
ipilimumab + nivolumab or vice
versa (NCT02224781)
Anti-PD-L1 (MPDL3280A) +/−
bevacizumab versus sunitinib in
advanced RCC. (NCT01984242)
Nivolumab plus sunitinib, pazopanib,
or ipilimumab in subjects with
metastatic RCC (NCT01472081)
Pembrolizumab plus axitinib in
advanced RCC (NCT02133742)